Pancreatic Cancer Research

ResearcherFukushima Medical UniversityActive in the last 2 years

Tadayuki J. Takagi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0696-5973; OpenAlex author ID A5026380573. Sources: OpenAlex.

Their work

Papers
20 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 20

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. A Systemic Review and Meta-analysis of the Incidence Rate of Interstitial Lung Disease in Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine… Co-author DOI 10.2169/internalmedicine.5084-24↗
  3. Prediction System for KRAS Mutation Detection in Circulating Tumor DNA in Unresectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17751↗
  4. Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. Co-author DOI 10.5387/fms.24-00011↗
  5. Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from … Co-author DOI 10.1186/s12885-023-10781-x↗
  6. A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fin… Co-author DOI 10.5946/ce.2022.019↗
  7. The Complement C3a-C3a Receptor Axis Regulates Epithelial-to-Mesenchymal Transition by Activating the ERK Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15587↗
  8. Intracellular C3 Modulates EMT via the Akt/Smad Pathway in Pancreatic Cancer Cells. First author DOI 10.21873/anticanres.16081↗
  9. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. First author DOI 10.5387/fms.2021-32↗
  10. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. First author DOI 10.1186/s12885-021-09069-9↗
  11. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospectiv… Co-author DOI 10.1007/s00280-019-03983-3↗
  12. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2018.9626↗
  13. Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23377↗
  14. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy. Co-author DOI 10.3892/mco.2018.1696↗
  15. Endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. First author DOI 10.5387/fms.2018-14↗
  16. Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. First author DOI 10.5387/fms.2017-04↗
  17. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2016.09.003↗
  18. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. First author DOI 10.3892/ol.2016.4381↗
  19. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. Co-author DOI 10.1007/s00534-011-0457-7↗
  20. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-g… Co-author DOI 10.1007/s10147-011-0197-3↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromasa Ohira · 19 shared papers, 2011–2025 · strength 2.15
  2. Mitsuru Sugimoto · 17 shared papers, 2016–2025 · strength 2.10
  3. Rei Suzuki · 17 shared papers, 2011–2025 · strength 1.90
  4. Hiroyuki Asama · 12 shared papers, 2016–2025 · strength 1.56
  5. Hiroki Irie · 10 shared papers, 2018–2025 · strength 1.31
  6. Hiroshi Shimizu · 3 shared papers, 2025 · strength 0.68
  7. Kentaro Sato · 3 shared papers, 2025 · strength 0.68
  8. Yuichi Waragai · 5 shared papers, 2016–2025 · strength 0.46
  9. Rei Ohira · 2 shared papers, 2025 · strength 0.46
  10. Shigeru Marubashi · 3 shared papers, 2018–2023 · strength 0.30
  11. Rei Suzuki · 1 shared paper, 2025 · strength 0.23
  12. Atsushi Masamune · 2 shared papers, 2016–2018 · strength 0.12
  13. Ya’an Kang · 1 shared paper, 2016 · strength 0.05
  14. Jason B. Fleming · 1 shared paper, 2016 · strength 0.05
  15. Atsushi Irisawa · 2 shared papers, 2011–2012 · strength 0.05
  16. Masanori Terashima · 2 shared papers, 2011–2012 · strength 0.05
  17. Hisahito Endo · 1 shared paper, 2012 · strength 0.03
  18. Mitsukazu Gotoh · 1 shared paper, 2012 · strength 0.03
  19. Takeru Wakatsuki · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.